



CL 2016/41-RVDF  
December 2016

**TO:** Codex Contact Points  
Interested International Organisations

**FROM:** Secretariat, Codex Alimentarius Commission  
FAO, Viale delle Terme di Caracalla, 00153 Rome, Italy

**SUBJECT:** **Request for Comments/Information on Priority List of Veterinary Drugs for Evaluation or Reevaluation by JECFA**

**DEADLINE:** **15 February 2018**

**COMMENTS:** **To:** U.S. Codex Office,  
Food Safety and Inspection Service  
US Department of Agriculture Secretariat  
Room 4861, South Building,  
14<sup>th</sup> Independence Avenue, S.W.,  
Washington DC 20250, USA  
E-mail: [CCRVDf-USSEC@fsis.usda.gov](mailto:CCRVDf-USSEC@fsis.usda.gov)

**Copies to:** Secretariat  
Codex Alimentarius Commission  
Joint FAO/WHO Food Standards  
Programme  
Viale delle Terme di Caracalla  
00153 Rome, Italy  
E-mail: [codex@fao.org](mailto:codex@fao.org)

## BACKGROUND

1. CCRVDf23 (17-21 October 2016) agreed to forward the Priority List of Veterinary Drugs for Evaluation or Reevaluation by JECFA to CAC40 for approval (REP17/RVDF paras 113, 138 and Appendix VI Part A).
2. CCRVDf23 agreed to add information on the registration of the compound as a pesticide and, where applicable, information on the JMPR evaluation to the form requesting information on compounds for evaluation by JECFA, attached to the CL requesting proposals for inclusion in the Priority List (REP17/RVDF para. 27).

## REQUEST FOR COMMENTS/INFORMATION

3. Governments and interested organizations are invited to make proposals for veterinary drugs to be included to the priority list for subsequent recommendation to JECFA for evaluation or re-evaluation and to provide the information according to the template in the Annex to this document.
4. According to Section 3.1.2 "Establishment of Priority List" of the *Risk Analysis Principles applied by the Codex Committee on Residues of Veterinary Drugs in Foods* (Procedural Manual of the Codex Alimentarius Commission), in order to appear on the priority list of veterinary drugs for the establishment of a MRL, the proposed veterinary drug shall meet some or all of the following criteria:
  - A Member has proposed the compound for evaluation (a template for information recommended for consideration in the priority list by Codex Committee on Residues of Veterinary Drugs in Foods has been completed and be available to the Committee);
  - A Member has established good veterinary practices with regard to the compound;
  - The compound has the potential to cause public health and/or international trade problems;
  - The compound is available as a commercial product; and
  - There is a commitment that a dossier will be made available.
5. Governments and international organizations wishing to provide comments should do so in sending their comments **by e-mail** to the above addresses before **15 February 2018**.

## ANNEX

## TEMPLATE FOR INFORMATION NECESSARY FOR PRIORITIZATION BY CCRVDF

**ADMINISTRATIVE INFORMATION**

1. Member(s) submitting the request for inclusion
2. Veterinary drug names
3. Trade names
4. Chemical names and CAS registry number
5. Names and addresses of basic producers

**PURPOSE, SCOPE AND RATIONALE**

6. Identification of the food safety issue (residue hazard)
7. Assessment against the criteria for the inclusion on the priority list

**RISK PROFILE ELEMENTS**

8. Justification for use
9. Veterinary use pattern, including information on approved uses if available (*this should include product labels or other evidence of official use authorization*)
10. Commodities for which Codex MRLs are required

**RISK ASSESSMENT NEEDS AND QUESTIONS FOR THE RISK ASSESSORS**

11. Specific request to risk assessors

**AVAILABLE INFORMATION<sup>1</sup>**

12. Countries where the veterinary drugs are registered
13. National/Regional MRLs or any other applicable tolerances
14. List of data (pharmacology, toxicology, metabolism, residue depletion, analytical methods) available (*this should include a list of the data available with the full study titles and whether the compound is also registered as pesticide and, as appropriate, has been evaluated or scheduled for evaluation or re-evaluation by JMPR*)

**TIMETABLE**

15. Date when data could be submitted to JECFA

---

<sup>1</sup> When preparing a preliminary risk profile, Member(s) should take into account the updated data requirement, to enable evaluation of a veterinary drug for the establishment of an ADI and MRLs, published by JECFA.